Drugs that contain Tasimelteon
1. Drug name - HETLIOZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(2 months from now) | |
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| CN1152679C | VANDA PHARMS INC | Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents |
Dec, 2017
(4 years ago) | |
| CN1239886A | VANDA PHARMS INC | Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents |
Dec, 2017
(4 years ago) | |
| EP1027043B1 | VANDA PHARMS INC | Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents |
Dec, 2017
(4 years ago) | |
| EP1027043A1 | VANDA PHARMS INC | Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents |
Dec, 2017
(4 years ago) | |
| EP1027043A4 | VANDA PHARMS INC | Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents |
Dec, 2017
(4 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(11 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(12 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(12 years from now) | |
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(12 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
Treatment: Treatment of non-24-hour sleep-wake disorder; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | CAPSULE;ORAL | Prescription |
2. Drug name - HETLIOZ LQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(2 months from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(12 years from now) | |
| CN1152679C | VANDA PHARMS INC | Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents |
Dec, 2017
(4 years ago) | |
| CN1239886A | VANDA PHARMS INC | Benzodioxolyl, Benzofuran, Dihydro Benzofuran And Benzodioxane Compounds Melatonin Agents |
Dec, 2017
(4 years ago) | |
| EP1027043B1 | VANDA PHARMS INC | Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents |
Dec, 2017
(4 years ago) | |
| EP1027043A1 | VANDA PHARMS INC | Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents |
Dec, 2017
(4 years ago) | |
| EP1027043A4 | VANDA PHARMS INC | Benzodioxole, Benzofuran, Dihydrobenzofuran, And Benzodioxane Melatonergic Agents |
Dec, 2017
(4 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(10 years from now) | |
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(11 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(12 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(12 years from now) | |
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(12 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| US11202770 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Dec, 2040
(18 years from now) | |
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 4MG/ML | SUSPENSION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.